

FORM PTO-1449  <b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1468R1D1	Serial No. <b>828739</b> not yet assigned
		Applicant Ashkenazi et al.	
		Filing Date 09 Apr 2001	Group <b>1644</b> not yet assigned

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
<i>dal</i>	* 1	4,816,567	28.03.89	Cabilly et al.	530	387.3
<i>dal</i>	* 2	4,855,235	08.08.89	Takahashi et al.	435	240.27
<i>dal</i>	* 3	5,071,759	10.12.91	Rothman et al.	435	240.27
<i>dal</i>	* 4	5,153,118	06.10.92	Wright, Jr. et al.	435	7.23
<i>dal</i>	* 5	5,158,885	27.10.92	Bradstock et al.	435	240.27
<i>dal</i>	* 6	5,622,701	22.04.97	Berg, E.	424	153.1
<i>dal</i>	* 7	6,030,945	29.02.00	Ashkenazi, A.	514	12
<i>dal</i>	* 8	6,072,047	06.06.00	Rauch et al.	536	23.53

JC979 U.S. PTO  
 09/828739  
 04/09/01

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
<i>dal</i>	* 9	WO 91/02805	07.03.91	PCT	—	—
<i>dal</i>	*10	WO 93/22343	11.11.93	PCT	—	—
<i>dal</i>	*11	WO 97/05170	13.02.97	PCT	—	—
<i>dal</i>	*12	WO 97/25428	17.07.97	PCT	—	—
<i>dal</i>	*13	WO 99/03992	28.01.99	PCT	—	—
<i>dal</i>	*14	WO 99/09165	25.02.99	PCT	—	—
<i>dal</i>	*15	WO 99/64461	16.12.99	PCT	—	—

**OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)**

<i>dal</i>	*16	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoaderisin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
	*17	Chuntharapai and Kim, "Generation of Monoclonal Antibodies to Chemokine Receptors" <u>Methods in Enzymology</u> 288:15-27 (1997)
	*18	Ellis, S., "Recognition of HLA-B27 and Related Antigen by a Monoclonal Antibody" <u>Human Immunology</u> 5:49-59 (1982)
	*19	Emery et al., "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand Trail" <u>Journal of Interferon and Cytokine Research</u> (Abstract No. 2.17 from the 7th Intl. Tumor Necrosis Factor Congress May 17-21) 18(5):A-47 (May 1998)
	*20	Fishwild et al., "High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice" <u>Nature Biotechnology</u> 14(7):845-851 (Jul 1996)
	*21	Glassy, M., "Production methods for generating human monoclonal antibodies" <u>Human Antibodies &amp; Hybridomas</u> 4(4):154-165 (Oct 1993)
	*22	Hoogenboom and Winter, "By-passing immunisation: human antibodies from synthetic repertoires of germline V <sub>H</sub> gene segments rearranged in vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)
	*23	Jolliffe, L., "Humanized antibodies: enhancing therapeutic utility through antibody engineering" <u>International Reviews of Immunology</u> 10(2-3):241-250 (1993)
<i>dal</i>	*24	Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)

Examiner <i>Daniel A. Schneider</i>	Date Considered <i>9/28/02</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

\* FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1468R1D1

Serial No.

not yet assigned

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

09 Apr 2001

Group

not yet assigned

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

<i>Del</i>	*25	Kohler and Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <u>Nature</u> 256:495-497 (August 7, 1975)
	*26	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
	*27	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain" <u>Current Biology</u> 7:1003-1006 (1997)
	*28	Mehta et al., "Simultaneous production of antibodies against T <sub>3</sub> and T <sub>4</sub> in a single animal; their characteristics and usefulness in radioimmunoassay" <u>International Journal of Radiation Applications &amp; Instrumentation - Part B, Nuclear Medicine &amp; Biology</u> 16(6):599-601 (1989)
	*29	Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice" <u>Nature Genetics</u> 15:146-156 (Feb 1997)
	*30	Milstein, C., "The Wellcome Foundation Lecture, 1980: monoclonal antibodies from hybrid myelomas" <u>Proceedings of the Royal Society of London - Series B: Biological Sciences</u> 211(1185):393-412 (Mar 27, 1981)
	*31	Olsson and Kaplan, "Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5429-5431 (1980)
	*32	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)
	*33	Peterson, N., "Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies" <u>Laboratory Animal Science</u> 46(1):8-14 (Feb. 1996)
	*34	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
	*35	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)
	*36	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
	*37	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997)
	*38	Steinitz et al., "EB virus-induced B lymphocyte cell lines producing specific antibody" <u>Nature</u> 269(5627):420-422 (Sep 29, 1977)
	*39	Vaughan et al., "Human Antibodies With Sub-nanomolar Affinities Isolated From a Large Non-immunized Phage Display Library" <u>Nature Biotechnology</u> 14:309-314 (1996)
<i>↓</i>	*40	Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)

Examiner

*David A Saunders*

Date Considered

*9/28/02*

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.